Last reviewed · How we verify
Trimbow pMDI
Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.
Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Trimbow pMDI |
|---|---|
| Sponsor | Medicines Evaluation Unit Ltd |
| Drug class | Triple combination inhaler (ICS/LABA/LAMA) |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The inhaled corticosteroid reduces airway inflammation and mucus production. The long-acting beta-2 agonist and long-acting muscarinic antagonist work synergistically to relax bronchial smooth muscle through different pathways, providing sustained bronchodilation. This triple combination addresses multiple pathophysiological mechanisms in COPD to improve airflow and reduce exacerbations.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Oral candidiasis
- Dysphonia
Key clinical trials
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
- A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trimbow pMDI CI brief — competitive landscape report
- Trimbow pMDI updates RSS · CI watch RSS
- Medicines Evaluation Unit Ltd portfolio CI